LOCALLY ADVANCED UROTHELIAL CARCINOMA
Clinical trials for LOCALLY ADVANCED UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy after bladder cancer surgery: could it keep the cancer away?
Disease control OngoingThis Phase 3 trial tests whether the immunotherapy drug pembrolizumab (Keytruda) can help prevent bladder cancer from returning after surgery. About 739 patients with muscle-invasive or locally advanced urothelial cancer are randomly assigned to receive pembrolizumab or just be o…
Matched conditions: LOCALLY ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
New drug duo shows promise for tough bladder cancer
Disease control OngoingThis study tests a combination of two drugs—tazemetostat and pembrolizumab—in people with advanced bladder cancer that has spread. The goal is to find the best dose and see if the combo works better than pembrolizumab alone. About 30 adults with locally advanced or metastatic uro…
Matched conditions: LOCALLY ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug cocktail targets Hard-to-Treat bladder cancer
Disease control OngoingThis early-phase trial is testing a combination of two drugs—erdafitinib and enfortumab vedotin—in 24 people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. Erdafitinib blocks a faulty protein that helps cancer grow, while enfortumab vedotin de…
Matched conditions: LOCALLY ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New triple therapy for bladder cancer shows promise in early trial
Disease control OngoingThis early-phase study tests a combination of three drugs (tremelimumab, durvalumab, and belinostat) in people with advanced bladder cancer that has spread or cannot be removed surgically. The main goal is to find the safest dose and understand side effects. About 9 adults who ha…
Matched conditions: LOCALLY ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Bladder cancer breakthrough? trial tests stopping immunotherapy early
Disease control OngoingThis study looks at whether people with advanced bladder cancer can stop taking immunotherapy drugs (like pembrolizumab or nivolumab) after about a year instead of continuing indefinitely. The goal is to see if stopping early leads to similar survival rates while reducing side ef…
Matched conditions: LOCALLY ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the saf…
Matched conditions: LOCALLY ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Bladder cancer combo trial pulled before it even started
Disease control TerminatedThis was a small early-stage trial testing a mix of three drugs (N-803, pembrolizumab, and enfortumab vedotin) for people with advanced bladder cancer who had not yet received any treatment. The goal was to see if the combination was safe and could slow cancer growth. However, th…
Matched conditions: LOCALLY ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can less be more? new study tests a gentler dosing schedule for advanced bladder cancer drug
Disease control OngoingThis pilot study is testing whether a less frequent dosing schedule of the drug enfortumab vedotin (EV), given alone or with pembrolizumab, can still control advanced bladder cancer. About 60 adults with locally advanced or metastatic urothelial carcinoma will receive EV on a mod…
Matched conditions: LOCALLY ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New cocktail of cancer drugs tested for tough bladder tumors
Disease control OngoingThis early-stage study is testing a combination of three drugs—sacituzumab tirumotecan, enfortumab vedotin, and pembrolizumab—in people with advanced bladder cancer that has spread or cannot be surgically removed. The trial has two parts: first, to find safe doses of the two-drug…
Matched conditions: LOCALLY ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could a common blood pressure pill boost immunotherapy for bladder cancer?
Disease control OngoingThis phase 2 trial is testing whether adding propranolol, a common blood pressure drug, to standard immunotherapy can help control advanced bladder cancer. The study enrolled 6 adults with urothelial carcinoma that has spread or cannot be removed by surgery. Researchers are prima…
Matched conditions: LOCALLY ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New targeted drug aims to fight hard-to-treat bladder cancers
Disease control OngoingThis study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…
Matched conditions: LOCALLY ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Can a gene test tell who responds to immunotherapy for bladder cancer?
Knowledge-focused OngoingThis small phase II trial is studying whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well patients with advanced bladder cancer respond to the immunotherapy drug nivolumab. Six participants with metastatic urothelial cancer whose tu…
Matched conditions: LOCALLY ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC